Eli Lilly, now the world's most valuable healthcare company by market capitalization, has seen its shares soar 62.5% this year due to high demand for their diabetes drug Mounjaro. The company plans to invest $5.3 billion to expand production capacity for its widespread obesity and diabetes drugs - the most significant investment of its kind in U.S.